Introduction
Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm (MPN) characterized by thrombocytosis. Patients are at higher risk of thrombosis and hemorrhage. They also have diseaserelated symptoms, which are difficult to manage with standard therapies. Therapeutic approaches address risks of thrombosis and hemorrhage, without increasing transformation into myelofibrosis (PET-MF) or acute myeloid leukemia (AML) [1] [2] [3] . Low-dose aspirin with hydroxycarbamide (HC) is recommended first-line therapy in high-risk patients, supported by data from randomized trials 3, 4 .
Approximately 20% of ET patients become HC-intolerant or resistant; patients with resistance appear to be at increased risk of disease transformation and reduced overall survival 5 . No prospective trial data exists to guide management of ET patients who are HC-resistant or intolerant; treatment options are limited, and several second-line treatment options are associated with increased risk of disease transformation 2, 3, 6 .
The discovery of the Janus kinase (JAK2V617F) mutation provided the first genetic marker of the malignant clone in MPN [7] [8] [9] . Furthermore, other key driver mutations associated with ET, affecting thrombopoietin receptor MPL and calreticulin (CALR) also lead to increased JAK2 signaling 14 . The JAK1/2 inhibitor, ruxolitinib, was effective in reducing spleen volume, controlling blood counts and improving symptoms in MF and PV patients [15] [16] [17] . Ruxolitinib treatment may also result in a survival advantage for patients with MF 18, 19 . A previous non-randomized study in 39 ET patients, resistant or intolerant to HC, demonstrated that ruxolitinib lowered both platelet and white cell counts and the most effective starting dose was 25mg bd 20 .
We conducted a randomized, phase II trial to evaluate the activity and safety of ruxolitinib vs Best Available Therapy (BAT) in two different patient populations (ET and PV): A randomized study of best Available therapy versus JAK inhibition in patients with high-risk PV or ET who are resistant or intolerant to HydroxyCabamide (MAJIC). The study utilized an efficient framework of a basket trial design, permitting the separate evaluation of two study populations. Here we present safety and efficacy data for the ET population, so-called MAJIC-ET.
Patients and Methods
Trial design An independent, parallel, open-label, randomized controlled trial of ruxolitinib vs BAT was implemented (Supplemental Figure S1 ). Patients aged ≥18 with high-risk ET or PV, who met modified criteria for intolerance or resistance to HC 21 ( Supplemental Table S1 ), were recruited. MAJIC-PV arm is on-going. High-risk ET was defined by standard criteria ( Supplemental Table S2 ). Patients were stratified by JAK2V617F status and randomized 1:1 to receive either ruxolitinib (starting dose 25mg twice daily (bd) or 20mg bd, if baseline platelets were 100-200×10 9 /L) or BAT. Inclusion and exclusion criteria are presented ( Supplemental Table S3 ). The trial was registered at www.isrctn.com (ISRCTN61925716) and reviewed by an independent research ethics committee. All participants gave written informed consent in accordance with the Declaration of Helsinki. Trial data was analyzed by statisticians at the Cancer Research UK Clinical Trials Unit (University of Birmingham) and Quality of Life (QoL) analysis performed by statisticians at the Mayo Clinic, Scottsdale, Phoenix. Ruxolitinib was provided free of charge by Novartis. All authors had access to primary clinical trials data and approved the final version of manuscript.
Outcome measures
The primary outcome measure was achievement of Complete Response (CR) as defined by European Leukemia Net (ELN) criteria within 1 year of treatment 22 . CR in ET patients was defined by achieving all of the following criteria: platelet count ≤400×10 9 /L; normal spleen size on imaging; white blood cell count ≤10×10 9 /L. Secondary outcomes included Partial Response (PR) per ELN criteria within 1
year of treatment, duration of response (both CR and PR) and overall response (i.e. CR&PR), toxicity profile of ruxolitinib based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4, dose intensity, histological response, molecular response; hemorrhagic and thromboembolic events, disease transformations, QoL and disease symptom burden, overall and progression free survival. The safety population included all patients who received at least one dose of protocol treatment. Hemorrhagic and thrombotic events were centrally reviewed. QoL and symptom assessment questionnaires: 10-item Myeloproliferative Neoplasm Symptom Assessment Form (MPN-10) Total Symptom Score (TSS) 23 , EQ-5D 24 and M.D. Anderson Symptom Inventory (MDASI) 25 were completed at baseline (pre-treatment, 7 consecutive days for the MPN-10 and once for the other questionnaires), 2 and 4 months post randomization and continued 4 monthly whilst on trial. Overall symptom response was defined as at least a 50% reduction in TSS from baseline (average of the 7 baseline days with at least 4 of 7 days scored) at any post-baseline time point up to Month 12.
Sample size justification and statistical analysis Sample size calculations were based upon rates from a previous phase II study 20 using an one-sided normal test without continuity correction and unpooled variance. CR rate for controls was estimated at 30%. A clinically significant improvement was considered to be 20%. Thus, assuming CR rates in the control and treatment group were 30% and 50%, 55 patients were required in each arm to detect a clinically significant difference of 20% with 82% statistical power at 10% level of significance. As this is a randomized screening trial to evaluate a direct, but nondefinitive comparison, with the aim of screening for promising signal of activity in ruxolitinib, a relaxed onesided significance level of 10% was utilized 26 . Allowing for a 5% drop out rate, 116 patients were required.
P<.10 was considered significant for the primary outcome. For other analyses, two-sided tests were 
Treatment and assessments
Ruxolitinib was initiated based on baseline platelet count. BAT was assigned according to physician's choice but had to be an active agent, change of and combination of BAT therapies was permitted with the aim of achieving a CR. No crossover of BAT to ruxolitinib was permitted. Low-dose aspirin 6 BLOOD/2017/785790 v 2.0 Resubmission MAJIC ET_Main Manuscript (75mg od) was advised unless contraindicated. Protocol-specified dose reductions for ruxolitinib were in place and patients allowed to re-escalate if toxicity had resolved. Lowest permitted dose of ruxolitinib was 5mg once-daily. Hematological response was assessed 2 weekly for 3 months, then 6 weekly in order to determine the primary outcome of CR during year 1 (cut-off week 54).
Ultrasound was performed at baseline and centrally reviewed. If splenomegaly was present at baseline repeat ultrasound showing resolution was required for CR. Ruxolitinib continued beyond 1
year if CR or PR were maintained. Those discontinuing ruxolitinib moved to BAT arm for follow-up.
Patients who transformed to PET-MF, myelodysplastic syndrome (MDS) or AML discontinued the trial but were followed for survival.
Assays for JAK2V617F, CALR and MPL mutation allele burden was quantified using next generation sequencing as previously described 27 . An analysis of histological features is currently being performed and this data is not being presented as part of this manuscript. (Table 1) , except for the ruxolitinib arm with longer disease-duration and lower hemoglobin. Six patients were excluded from mITT analysis: 4 withdrew without treatment (2 did not wish to be on BAT arm, one ineligible, one had transformed to PET-MF) and 2 did not start treatment within one year from randomization. All CALR indels and MPL mutations are provided in Supplemental Table S4 .
Results

Patient
Trial Treatment
For patients receiving ruxolitinib, the mean dose intensity of ruxolitinib during year one was 19mg bd (Figure 1 ). The most common BAT therapies utilized at least once included HC in 37/52 (71.1%), anagrelide in 25/52 (48.1%) and interferon in 21/52 (40.4%) patients.
Patient disposition
Patient disposition at the time of analysis (2 year follow up) is shown in Figure 2 . Thirty BAT patients (57.7%) switched their initially assigned therapy at least once and there were 86 switches across the BAT group. In total, 45 patients (49.5%) discontinued treatment, with 40 discontinuations occurring within the first treatment year. Thirty-five patients (60.3%) receiving ruxolitinib and 10 patients (19.2%) receiving BAT discontinued treatment. The main reasons for discontinuation in the ruxolitinib arm were loss of response (11/35 (31.4%)) and transformation (9/35 (25.7%)). The main reasons for discontinuation in the BAT arm were transformation (3/10 (30%]) and death (2/10 (20%)). Discontinuations and therapy switches are shown in Table 2 . factor was shown to be significant and did not change the treatment effect ( Supplemental Table S5 ).
Efficacy analysis
Thrombosis, hemorrhage and disease transformation After 2 years of follow up transformation to PET-MF occurred in 8 ruxolitinib vs. 5 BAT treated patients. Transformation to AML was seen in 1 patient who received ruxolitinib. Transformation-free probability was not significantly different between the two arms (P=.29; Supplemental Figure S2A ).
Concerning thrombosis and hemorrhage, following central review, 10 patients (17.2%) on the ruxolitinib arm experienced 11 thrombotic events compared to 3 patients (5.8%) on the BAT arm experiencing 5 events. Hemorrhagic events were 1 (1.7%) vs 5 (8.9%) for ruxolitinib and BAT patients respectively ( Table 3 ). Concerning thrombosis-free probability, the differences were borderline but not statistically significant (P =.09; Supplemental Figure S2B ). Hemorrhage was less frequent for patients treated with ruxolitinib, however this difference was also not significant (P =.14;
Supplemental Figure S2C ). Since all of these events are considered clinically relevant we performed Table S6 ).
Molecular responses (MR)
The mean baseline allele burdens for JAK2V617F, CALR or MPL mutation positive patients are displayed in Table 1 . At 12 months, or the last available sample during year 1, the overall mean allele burden had not changed significantly for any mutation in either treatment arm. However, 1 complete molecular response (CMR) and 1 partial molecular response (PMR) per ELN criteria were seen for JAK2V617F positive patients on the ruxolitinib arm and 2 CMRs and 1 PMR for CALR positive patients on ruxolitinib compared to 0 CMRs/PMRs for patients with these mutations receiving BAT. A JAK2V617F positive patient who achieved a PMR on ruxolitinib also had resolution of a cytogenetic abnormality at one year. There was no pattern of MR or progression with complete or partial hematological response or transformation, but 1 CALR positive patient who transformed to PET-MF had a CMR.
Impact on ET Related Disease Symptom Burden
Among 110 patients in the mITT cohort, 85 completed the baseline and at least one post-baseline questionnaire (ruxolitinib N=47, BAT N=38). While overall symptom response rate during the first 12 months did not significantly differ between arms (ruxolitinib 12/42 (29%) vs BAT 6/31 (19%), P=.37), maximum percentage TSS reduction at any point during the first 12 months of treatment was significantly greater for ruxolitinib compared to BAT (median reduction 32% vs 0%, P=.03, Figure 3A Table S7 ). Table S8 ).
There were 5 patient deaths in the ruxolitinib arm and 2 in the BAT arm, none were considered treatment related. The deaths in the BAT arm were due to multiple organ failure and cerebral hemorrhage. In the ruxolitinib arm, deaths were due to carcinomatosis combined with esophageal cancer, bowel infarction due to adhesions, acute left ventricular failure, ischemic cardiomyopathy and sepsis combined with pancreatic cancer.
Discussion
ET is often regarded as the most indolent of the Philadelphia negative MPNs, treatments offer improvements in blood counts and reduction in risk of thrombosis and hemorrhage with a lack of certainty regarding effects upon transformation to PET-MF and AML 2,3 . Criteria for resistance or intolerance to therapy with HC were originally developed to guide clinicians when to initiate secondline therapies; however, there is now evidence that HC resistant patients have a poor outlook 28 . In addition, disease-related symptom burden is increasingly recognized as an important disease feature, causing significant morbidity with few effective treatments [2] [3] [4] . In previous studies patients with MF gained a survival benefit with ruxolitinib, which also reduced spleen size and symptoms compared to BAT 18 Usual therapy choice in the second-line setting for ET would be anagrelide or interferon, however in order to perform a "real-life comparison" we allowed investigator choice. Overall the majority, 79%
(41/52), of BAT patients received one or both agents before or during the study. On-study BAT included in addition busulfan 32 P and HC; several international guidelines recommend busulfan or 32 P for older patients.
Proportions of patients reaching CR within one year were similar: 27 (46.5%) in the ruxolitinib arm vs 23 (44.2%) for BAT, with similar PR rates. Time to any first response (CR or PR) was significantly faster for patients treated with ruxolitinib (P=.01). A particularly interesting finding, as patients in CR who were randomized to receive ruxolitinib had to change therapy and potentially lost any preexisting response yet managed to attain CR faster than BAT patients who may not have changed therapy thus only needing to maintain response. In addition, BAT patients were also allowed to combine or to switch therapies and frequently did so. Importantly the duration of CR appeared shorter for ruxolitinib patients with a marginally significant value, while the duration of overall response (CR and PR) was not different between both arms. We confirm that HC resistant/intolerant ET patients have a high-risk of thrombosis, hemorrhage and transformation to PET-MF; event rates here being higher than reported in the non-resistant/intolerant patients e.g. PT-1 or ANAHYDRET studies 30, 31 . However, overall thrombosis, hemorrhage or transformation considered separately or together as a composite endpoint were not statistically different between the ruxolitinib and BAT. Furthermore, in a post hoc unplanned analysis for factor influencing transformation to PET-MF, only a leucocyte count <10x10 9 /L was significant.
Studies have reported that post-randomization exclusions of patients in randomized trials may affect trial results 32 , with some raising concerns that the investigated therapy might be favored 33, 34 .
However, in the MAJIC-ET trial, if we were to conduct a pure intention-to-treat (ITT) analysis, this would require imputation of missing response data for 6 BAT patients. Missing data imputation may bias estimates of treatment effects 35 . A commonly used technique is nonresponder imputation, which will attribute all 6 BAT patients as not achieving CR within a year. This will result in a less conservative ITT analysis of 23/58 CR (BAT) vs 27/58 CR, with p-value of .22 compared to the mITT analysis (p=.4). Our primary findings of no evidence of superiority of ruxolitinib were however consistent using either mITT or ITT analysis. Manuscript Molecular responses were uncommon in the first year of the trial, as described previously 20 .
However, ruxolitinib was associated with two CMR and one PMR in a CALR positive patient; this has not previously been reported. Transformation to PET-MF in one CALR positive patient, who achieved a CMR, presumably occurred due to the emergence of a different clone, consistent with patients reported with JAK2V617F positive chronic phase developing JAK2V617F negative AML 36 , and raises questions about the relevance and value of CMR in patients with ET.
Patterns of adverse events with ruxolitinib were similar to those already reported, most prevalent events related to hematological, nutritional and metabolic events. Infections were also more common with ruxolitinib therapy. There was no suggestion of imbalance between the two arms of MAJIC-ET for non-melanoma skin cancer as was previously noted in the RESPONSE trial 17 . Treatment discontinuation occurred more frequently for patients treated with ruxolitinib, with 35 patients discontinuing treatment compared to 9 discontinuations in the BAT arm. However, 30 BAT patients switched their initially assigned BAT treatment for various reasons, which indicates a similar rate of treatment ineffectiveness or intolerance. For the first time, we show baseline anemia predicted for treatment emergent anemia and thrombocytopenia.
Patients with ET have a high burden of symptoms, which have been consistently reported to affect their quality of life 37 . The symptom response rate, defined as a 50% reduction in TSS, during the first 12 months did not significantly differ between the two arms. However, maximum percentage TSS reduction during the first 12 months of treatment was significantly greater for ruxolitinib compared to BAT and was more rapid in the ruxolitinib arm. Longitudinally, mean TSS and individual symptom of pruritus were significantly lower for ruxolitinib, with trends observed for improved concentration, lower anxiety/depression and higher ability to perform usual activities for ruxolitinib arm compared to BAT indicating a novel and important benefit to ET patients of ruxolitinib therapy.
Limitations of our trial include that the trial reflected "real life practice" in use of diagnostic criteria and selection of BAT therapies. The majority of our centers used either BCSH (n=18) or WHO (n=10) or both (n=3) diagnostic criteria thus perhaps illustrating non-standardized diagnostic processes, however this is a second line study and BCSH/WHO criteria both perform equally well 29 in addition transformation was excluded at study entry. Guidelines recommend anagrelide or IFN as second line therapy for ET, many BAT patients had already been treated with these drugs (25 received interferon, 7 anagrelide and 7 both agents) before study entry, and overall 79% received them before or during the study. The use of HC as a BAT and frequent switching of BAT therapies in 30 BAT patients also reflect real-life constraints and limited treatment options for ET patients with resistance/intolerance to HC and highlight the need for newer therapies in this field. Manuscript
In conclusion, the MAJIC-ET trial suggests that ruxolitinib does not have improved treatment efficacy compared to BAT for most clinically relevant events. Symptom responses were superior with ruxolitinib therapy but there was no difference in this study for control of blood counts or other relevant endpoints such as transformation, thrombosis or hemorrhage.
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